# FDA Expands Trodelvy Approval to First-Line Metastatic Triple-Negative Breast Cancer

> fda · REPORTED · 2026-07-01

The FDA approved sacituzumab govitecan (Trodelvy) for newly diagnosed metastatic triple-negative breast cancer in patients whose tumors express Trop-2, and in combination with Keytruda for PD-L1-expressing tumors, representing a major first-line expansion of this antibody-drug conjugate. The approvals significantly broaden the addressable patient population for Trodelvy in one of the hardest-to-treat breast cancer subtypes.

About Gilead Sciences / Trodelvy: Trodelvy (sacituzumab govitecan) is a Trop-2-directed antibody-drug conjugate developed by Gilead Sciences for the treatment of metastatic triple-negative and other breast cancer subtypes.

- Company: Gilead Sciences / Trodelvy
- Sector: oncology
- Primary source: https://www.medicaldaily.com/fda-cancer-drug-approvals-q2-2026-breast-prostate-kidney-bladder-476161

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.